Ahren Innovation Capital

Ovo Labs is a biotechnology company focused on improving in vitro fertilization (IVF) success rates. It develops therapeutics that enhance egg quality, aiming to extend the window of opportunity for successful conception, particularly for women facing age-related fertility challenges.

Constructive Bio is a biotechnology company focused on genome rewriting to advance bioprocesses and biopharmaceuticals. By transforming living cells into biofactories, it aims to develop sustainable materials and therapeutics. The company possesses the capability to create virus-resistant organisms and utilizes its proprietary technology to biosynthesize various classes of enzymes, pharmaceuticals, and biomaterials. This innovative approach allows clients to reprogram the genetic code, enabling the production of natural molecules and exploring chemical spaces that are not accessible through traditional biological methods. Constructive Bio's work positions it at the forefront of biotechnology, paving the way for the next generation of sustainable solutions in the life sciences sector.

ZOE is a personalized nutrition company that focuses on improving individual health through a comprehensive understanding of the complex relationships between food, lifestyle, and health. It operates the world's largest nutrition-science study, as well as the ZOE Health Study, which initially addressed the impacts of COVID-19. The company offers at-home testing kits that assess gut health, blood fat, and blood sugar responses, providing personalized dietary recommendations based on individual reactions to food. Users receive tailored advice through an integrated mobile application, which includes food scores and guidance for making healthier dietary choices over a four-week period. ZOE's research is grounded in the understanding that gut bacteria significantly influence health, and its findings have been published in prestigious peer-reviewed journals. Through its innovative approach, ZOE aims to empower individuals to enhance their well-being and adopt healthier lifestyles.

Mentee Robotics specializes in the development of AI-powered humanoid robots designed to enhance productivity in both household and warehouse environments. The company integrates advanced robotics, sensing technology, and artificial intelligence to create robots that possess human-like dexterity and perception. These humanoid robots can be personalized and adapted to various tasks, facilitating activities such as lifting, carrying, organizing, and packing items in warehouses, as well as performing household chores. By leveraging natural human-robot interaction, Mentee Robotics aims to improve the efficiency of daily operations, making its technology valuable for both domestic and commercial use.

Sunfire is a company that specializes in developing and manufacturing systems for renewable industrial gas and fuel production. It focuses on creating substitutes for fossil fuels, such as mineral oil and natural gas, through innovative technologies like electrolyzers and solid oxide cells. These systems convert renewable electrical energy from sources like wind farms, hydropower plants, and photovoltaic systems into fuels and gases, including renewable hydrogen and syngas. By enabling the chemical, fuel, and steel industries to transition away from fossil energy, Sunfire aims to provide sustainable energy solutions that are available whenever needed, thus integrating renewable energy into existing infrastructures.

Mogrify is a biotechnology company that has created a proprietary suite of platform technologies aimed at advancing cellular reprogramming and maintaining cell identity. Developed over 12 years through an international research collaboration, its platforms, MOGRIFY and epiMOGRIFY, leverage big data, next-generation sequencing, and gene regulatory networks to predict the necessary transcription and growth factors for generating any desired human cell type from various sources. Mogrify's technology can enhance existing stem-cell programming methods or facilitate direct transdifferentiation between mature cell types, thereby generating functional cells for therapeutic applications. The company focuses on developing innovative in vivo reprogramming therapies targeted at conditions in ophthalmology, otology, metabolic diseases, and other degenerative disorders. Positioned to tap into a regenerative medicine market projected to reach $150 billion by 2028, Mogrify pursues commercialization through therapy development, co-development partnerships, and the application of its platforms in diverse therapeutic and non-therapeutic areas.

ZOE is a personalized nutrition company that focuses on improving individual health through a comprehensive understanding of the complex relationships between food, lifestyle, and health. It operates the world's largest nutrition-science study, as well as the ZOE Health Study, which initially addressed the impacts of COVID-19. The company offers at-home testing kits that assess gut health, blood fat, and blood sugar responses, providing personalized dietary recommendations based on individual reactions to food. Users receive tailored advice through an integrated mobile application, which includes food scores and guidance for making healthier dietary choices over a four-week period. ZOE's research is grounded in the understanding that gut bacteria significantly influence health, and its findings have been published in prestigious peer-reviewed journals. Through its innovative approach, ZOE aims to empower individuals to enhance their well-being and adopt healthier lifestyles.

Ambi Robotics is an artificial intelligence and robotics company founded in 2018 and headquartered in Berkeley, California. The company focuses on developing adaptable AI-powered robotics systems aimed at simplifying supply chain operations and addressing real-world challenges. Its product offerings include a robotic put wall, a configurable modular kitting line, and an advanced robot operating system that leverages simulation-to-reality AI. These innovations enable clients to enhance operational accuracy and efficiency while simultaneously reducing costs, ultimately supporting the growing demands of e-commerce.

Constructive Bio is a biotechnology company focused on genome rewriting to advance bioprocesses and biopharmaceuticals. By transforming living cells into biofactories, it aims to develop sustainable materials and therapeutics. The company possesses the capability to create virus-resistant organisms and utilizes its proprietary technology to biosynthesize various classes of enzymes, pharmaceuticals, and biomaterials. This innovative approach allows clients to reprogram the genetic code, enabling the production of natural molecules and exploring chemical spaces that are not accessible through traditional biological methods. Constructive Bio's work positions it at the forefront of biotechnology, paving the way for the next generation of sustainable solutions in the life sciences sector.

Phaidra, Inc. is a Seattle-based company established in 2019 that specializes in designing and developing artificial intelligence solutions for industrial sectors in the United States. The company focuses on providing AI and machine learning technologies aimed at enhancing performance in large-scale facilities. Phaidra's offerings include a virtual plant operator service that utilizes closed-loop AI control to empower operations teams in mission-critical environments. By analyzing extensive sensor data, Phaidra creates intelligent agents that automatically optimize and manage complex industrial processes. This innovative approach helps clients improve energy efficiency, increase safety and stability, and maximize operational yield, contributing to greater sustainability in their operations.

AI21 Labs Ltd., established in 2017 and headquartered in Tel Aviv-Yafo, Israel, specializes in developing artificial intelligence systems. The company focuses on creating generative AI and large language models, along with tools designed to understand and generate natural language effectively. Their primary product is an AI-based writing companion that comprehends context and meaning, transforming how users read and write by providing summaries and rewriting text for clarity. This empowers users to analyze and visualize abstract knowledge structures more efficiently.

Bitfount is a company that offers an innovative platform for federated data science and artificial intelligence, facilitating secure collaborations between organizations without the need for data sharing. Its platform employs federated learning and other privacy-preserving technologies, allowing data providers, data scientists, and governance teams to collaborate effectively. By enabling these partnerships, Bitfount aims to enhance the training of advanced AI models while maintaining the highest standards of privacy and data integrity. The company's focus on privacy-enhancing measures positions it as a leader in the field of data collaboration.

Heirloom is a company specializing in direct air capture technology aimed at enhancing the natural process of CO2 absorption from the atmosphere. Its innovative system accelerates limestone's ability to capture carbon dioxide, which is then stored permanently underground. The process operates using renewable energy, making it an environmentally friendly solution for carbon removal. Heirloom's technology is designed to capture and remove atmospheric CO2 at a gigaton scale, significantly reducing second-order impacts and minimizing extraction efforts. This approach allows clients to restore the atmosphere through natural processes, contributing to global efforts against climate change.

OxDX is a spinout that combines the power of single-molecule fluorescent microscopy with machine learning to identify pathogens in under a minute. They use a universal labelling system to light up everything in our sample, image the sample using super-resolution fluorescence microscopy, and analyse the images in our neural network.

Micropsi Industries GmbH is a Berlin-based robotics software company founded in 2014, specializing in machine learning solutions for robotics and process control. The company develops MIRAI, an advanced robot control system designed for complex assembly tasks. MIRAI enables robots to perform movements that adapt to subtle changes in their environment, utilizing cameras and force sensors. Unlike traditional programming methods, MIRAI's capabilities are acquired through a process of demonstration, correction, and repetition, allowing users to train robots without the need for coding or problem modeling. This innovative approach enhances productivity, ergonomics, and resilience in industrial settings, making it easier for businesses to automate tasks that were previously deemed too complex.

Cambridge Epigenetix Limited is a bioscience company based in Babraham, United Kingdom, specializing in epigenetic tools that aim to transform medical diagnostics. Founded in 2012 as a spin-out from the University of Cambridge, the company is pioneering the clinical applications of epigenetics, particularly through its innovative TrueMethyl technology. This includes oxidative bisulfite sequencing, which allows for the precise sequencing of hydroxymethyl cytosine and methylcytosine at single-base resolution. Cambridge Epigenetix offers a range of products, such as TrueMethyl 6 and TrueMethyl 24 kits, designed for the quantitative measurement and analysis of these critical epigenetic markers. The company’s research highlights the significance of 5-hydroxymethylcytosine as a biomarker for various diseases, including colorectal cancer, and aims to simplify diagnostic processes to a simple blood draw. The firm collaborates with third-party vendors and sells its products directly to business customers both in the UK and internationally.

ZOE is a personalized nutrition company that focuses on improving individual health through a comprehensive understanding of the complex relationships between food, lifestyle, and health. It operates the world's largest nutrition-science study, as well as the ZOE Health Study, which initially addressed the impacts of COVID-19. The company offers at-home testing kits that assess gut health, blood fat, and blood sugar responses, providing personalized dietary recommendations based on individual reactions to food. Users receive tailored advice through an integrated mobile application, which includes food scores and guidance for making healthier dietary choices over a four-week period. ZOE's research is grounded in the understanding that gut bacteria significantly influence health, and its findings have been published in prestigious peer-reviewed journals. Through its innovative approach, ZOE aims to empower individuals to enhance their well-being and adopt healthier lifestyles.

Adrestia Therapeutics Ltd is a biotechnology company based in Cambridge, United Kingdom, founded in 2017. The company specializes in developing therapeutics aimed at restoring the biological balance in damaged, diseased, and dying cells. Adrestia Therapeutics is recognized for its expertise in synthetic rescue, an innovative approach that decodes complex genetic networks to identify novel treatment strategies for various diseases. In addition to therapeutic development, the company provides basic and applied research, as well as experimental development services tailored to the biotechnology industry.

Nu Quantum Ltd is a company focused on developing quantum photonics hardware and quantum networking infrastructure to enhance the capabilities of quantum computing. Established in 2018 and based in Cambridge, United Kingdom, the company specializes in creating photon sources, detectors, and systems for quantum cryptography. Nu Quantum's innovations include nano-engineered materials for the generation of light at the quantum level and ultra-sensitive light detection systems. The company aims to establish the necessary infrastructure for interconnecting quantum computing cores into large distributed clusters, which is essential for scaling quantum computers. By developing full hardware solutions, including high-speed network interfaces and photonic switching fabrics, Nu Quantum seeks to facilitate the creation of entangled qubit networks. The company collaborates with leading quantum computing firms, governments, and research institutions to bring its advanced technologies to market, focusing on secure cryptographic key exchange and the future of information processing.

Rockley Photonics Limited, founded in 2013 and based in London, United Kingdom, specializes in developing silicon photonics technologies for diverse applications. The company focuses on creating integrated optical modules, sensors, and comprehensive solutions that cater to high-volume and dynamic market sectors. Rockley aims to revolutionize mobile health monitoring and machine vision with its next-generation sensing platforms, while also providing high-speed solutions for data communications. By leveraging its innovative photonic integrated circuits and associated modules, Rockley is positioned to address a wide array of vertical applications, believing that photonics will become as ubiquitous as microelectronics in the future. The company combines hardware with supporting electronics, software, application algorithms, and AI platforms, establishing a robust foundation for future developments across multiple industries.

Graphcore Limited is a hardware systems company founded in 2016 and headquartered in Bristol, United Kingdom, with additional offices in Palo Alto, London, Oslo, and Beijing. The company specializes in developing innovative microprocessors tailored for artificial intelligence and machine learning applications. Its flagship product, the Intelligence Processing Unit (IPU), features a unique architecture that significantly accelerates the execution of machine learning models, enabling developers to achieve performance levels orders of magnitude faster than traditional processors. Graphcore offers a range of products, including IPU-Accelerator cards for server integration and IPU-Appliance systems designed to enhance performance for inference tasks and training processes. This technology supports various users and applications, positioning Graphcore as a key player in the advancement of machine intelligence workloads.

Nu Quantum Ltd is a company focused on developing quantum photonics hardware and quantum networking infrastructure to enhance the capabilities of quantum computing. Established in 2018 and based in Cambridge, United Kingdom, the company specializes in creating photon sources, detectors, and systems for quantum cryptography. Nu Quantum's innovations include nano-engineered materials for the generation of light at the quantum level and ultra-sensitive light detection systems. The company aims to establish the necessary infrastructure for interconnecting quantum computing cores into large distributed clusters, which is essential for scaling quantum computers. By developing full hardware solutions, including high-speed network interfaces and photonic switching fabrics, Nu Quantum seeks to facilitate the creation of entangled qubit networks. The company collaborates with leading quantum computing firms, governments, and research institutions to bring its advanced technologies to market, focusing on secure cryptographic key exchange and the future of information processing.

Mogrify is a biotechnology company that has created a proprietary suite of platform technologies aimed at advancing cellular reprogramming and maintaining cell identity. Developed over 12 years through an international research collaboration, its platforms, MOGRIFY and epiMOGRIFY, leverage big data, next-generation sequencing, and gene regulatory networks to predict the necessary transcription and growth factors for generating any desired human cell type from various sources. Mogrify's technology can enhance existing stem-cell programming methods or facilitate direct transdifferentiation between mature cell types, thereby generating functional cells for therapeutic applications. The company focuses on developing innovative in vivo reprogramming therapies targeted at conditions in ophthalmology, otology, metabolic diseases, and other degenerative disorders. Positioned to tap into a regenerative medicine market projected to reach $150 billion by 2028, Mogrify pursues commercialization through therapy development, co-development partnerships, and the application of its platforms in diverse therapeutic and non-therapeutic areas.

6D.ai is a technology company specializing in the development of application programming interfaces for the augmented reality (AR) industry. Founded in 2017 and headquartered in San Francisco, California, the company focuses on creating a robust AR cloud platform that enables real-time, three-dimensional mapping of the environment using data sourced from standard smartphone cameras and mobile sensors. Its technology facilitates the construction of dense, interactive 3D meshes, allowing for multi-user AR experiences and enhancing spatial computing capabilities. By leveraging crowdsourced data, 6D.ai's solutions empower developers to create applications that seamlessly integrate with the physical world, thereby enriching user engagement and interaction. As of March 2020, 6D.ai operates as a subsidiary of Niantic, Inc.

Mogrify is a biotechnology company that has created a proprietary suite of platform technologies aimed at advancing cellular reprogramming and maintaining cell identity. Developed over 12 years through an international research collaboration, its platforms, MOGRIFY and epiMOGRIFY, leverage big data, next-generation sequencing, and gene regulatory networks to predict the necessary transcription and growth factors for generating any desired human cell type from various sources. Mogrify's technology can enhance existing stem-cell programming methods or facilitate direct transdifferentiation between mature cell types, thereby generating functional cells for therapeutic applications. The company focuses on developing innovative in vivo reprogramming therapies targeted at conditions in ophthalmology, otology, metabolic diseases, and other degenerative disorders. Positioned to tap into a regenerative medicine market projected to reach $150 billion by 2028, Mogrify pursues commercialization through therapy development, co-development partnerships, and the application of its platforms in diverse therapeutic and non-therapeutic areas.

Bicycle Therapeutics plc is a clinical-stage biopharmaceutical company based in Cambridge, United Kingdom, specializing in the development of a novel class of medicines known as Bicycles. These are synthetic short peptides designed to form two loops that stabilize their structure. The company's lead product candidate, BT1718, is a Bicycle Toxin Conjugate (BTC) currently undergoing Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. Other oncology candidates include BT5528, also a BTC in Phase I/IIa trials targeting EphA2, and BT8009, which is in preclinical studies targeting Nectin-4. Additionally, Bicycle is advancing THR-149, a plasma kallikrein inhibitor that has completed Phase I trials for diabetic macular edema. The company collaborates with various biopharmaceutical organizations to address therapeutic areas such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. Bicycle Therapeutics was incorporated in 2009 and aims to address significant unmet medical needs in oncology and beyond.

Adrestia Therapeutics Ltd is a biotechnology company based in Cambridge, United Kingdom, founded in 2017. The company specializes in developing therapeutics aimed at restoring the biological balance in damaged, diseased, and dying cells. Adrestia Therapeutics is recognized for its expertise in synthetic rescue, an innovative approach that decodes complex genetic networks to identify novel treatment strategies for various diseases. In addition to therapeutic development, the company provides basic and applied research, as well as experimental development services tailored to the biotechnology industry.

Bicycle Therapeutics plc is a clinical-stage biopharmaceutical company based in Cambridge, United Kingdom, specializing in the development of a novel class of medicines known as Bicycles. These are synthetic short peptides designed to form two loops that stabilize their structure. The company's lead product candidate, BT1718, is a Bicycle Toxin Conjugate (BTC) currently undergoing Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. Other oncology candidates include BT5528, also a BTC in Phase I/IIa trials targeting EphA2, and BT8009, which is in preclinical studies targeting Nectin-4. Additionally, Bicycle is advancing THR-149, a plasma kallikrein inhibitor that has completed Phase I trials for diabetic macular edema. The company collaborates with various biopharmaceutical organizations to address therapeutic areas such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. Bicycle Therapeutics was incorporated in 2009 and aims to address significant unmet medical needs in oncology and beyond.

Cambridge Epigenetix Limited is a bioscience company based in Babraham, United Kingdom, specializing in epigenetic tools that aim to transform medical diagnostics. Founded in 2012 as a spin-out from the University of Cambridge, the company is pioneering the clinical applications of epigenetics, particularly through its innovative TrueMethyl technology. This includes oxidative bisulfite sequencing, which allows for the precise sequencing of hydroxymethyl cytosine and methylcytosine at single-base resolution. Cambridge Epigenetix offers a range of products, such as TrueMethyl 6 and TrueMethyl 24 kits, designed for the quantitative measurement and analysis of these critical epigenetic markers. The company’s research highlights the significance of 5-hydroxymethylcytosine as a biomarker for various diseases, including colorectal cancer, and aims to simplify diagnostic processes to a simple blood draw. The firm collaborates with third-party vendors and sells its products directly to business customers both in the UK and internationally.